Literature DB >> 29760228

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.

Subodh Verma1,2, Deepak L Bhatt3, Stephen C Bain4, John B Buse5, Johannes F E Mann6, Steven P Marso7, Michael A Nauck8, Neil R Poulter9, Richard E Pratley10, Bernard Zinman11, Marie M Michelsen12, Tea Monk Fries12, Søren Rasmussen12, Lawrence A Leiter13,14.   

Abstract

Entities:  

Keywords:  atherosclerosis; diabetes mellitus, type 2; glucagon-like peptide 1; liraglutide; myocardial infarction

Mesh：

Substances：

Year:  2018        PMID： 29760228     DOI： 10.1161/CIRCULATIONAHA.118.033898

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  17 in total

1.  Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitation-Contradictory or Complementary?

Authors:  Gilbert H L Tang; Subodh Verma; Deepak L Bhatt
Journal:  JAMA Cardiol       Date:  2019-04-01       Impact factor: 14.676

Review 2.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

3.  Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.

Authors:  Subodh Verma; Stephen C Bain; John B Buse; Thomas Idorn; Søren Rasmussen; David D Ørsted; Michael A Nauck
Journal:  JAMA Cardiol       Date:  2019-12-01       Impact factor: 14.676

4.  Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.

Authors:  Marc D Samsky; Robert J Mentz; Amanda Stebbins; Yuliya Lokhnygina; Aaron W Aday; Neha J Pagidipati; W Schuyler Jones; Brian G Katona; Manesh R Patel; Rury R Holman; Adrian F Hernandez; Jorge Antonio Gutierrez
Journal:  Atherosclerosis       Date:  2021-11-01       Impact factor: 5.162

Review 5.  Polyvascular Disease: Reappraisal of the Current Clinical Landscape.

Authors:  J Antonio Gutierrez; Aaron W Aday; Manesh R Patel; W Schuyler Jones
Journal:  Circ Cardiovasc Interv       Date:  2019-12-13       Impact factor: 6.546

6.  Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Authors:  Takayoshi Kanie; Atsushi Mizuno; Yoshimitsu Takaoka; Takahiro Suzuki; Daisuke Yoneoka; Yuri Nishikawa; Wilson Wai San Tam; Jakub Morze; Andrzej Rynkiewicz; Yiqiao Xin; Olivia Wu; Rui Providencia; Joey Sw Kwong
Journal:  Cochrane Database Syst Rev       Date:  2021-10-25

7.  Antithrombotic therapy in diabetes: which, when, and for how long?

Authors:  Ramzi A Ajjan; Noppadol Kietsiriroje; Lina Badimon; Gemma Vilahur; Diana A Gorog; Dominick J Angiolillo; David A Russell; Bianca Rocca; Robert F Storey
Journal:  Eur Heart J       Date:  2021-06-14       Impact factor: 29.983

8.  Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes.

Authors:  Daniella C Terenzi; Mohammed Al-Omran; Adrian Quan; Hwee Teoh; Subodh Verma; David A Hess
Journal:  JACC Basic Transl Sci       Date:  2018-11-05

9.  Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Authors:  Subodh Verma; Stephen C Bain; Tea Monk Fries; C David Mazer; Michael A Nauck; Richard E Pratley; Søren Rasmussen; Hans A Saevereid; Bernard Zinman; John B Buse
Journal:  Diabetes Obes Metab       Date:  2019-04-02       Impact factor: 6.577

10.  Epidemiology of Peripheral Artery Disease and Polyvascular Disease.

Authors:  Aaron W Aday; Kunihiro Matsushita
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.